위축성 위염 혹은 위암에 미치는 프로톤펌프억제제의 영향: Safe 측면 = Special Review : Effects of Proton Pump Inhibitors on Atrophic Gastritis and Gastric Cancer: Safe Perspective

다국어 초록 (Multilingual Abstract)

Proton pump inhibitors (PPIs) are widely used over 20 years for management of symptoms due to acid related diseases such aspeptic ulcer and reflux esophagitis. Serious adverse events are extremely rare for short-term PPIs use. Recently, as long-term PPIsuse increase, diverse reports have been reported on adverse event related with long-term PPIs use. Long-term PPIs use is generally referred as use of PPIs more than 1 year. Secondary hypergastrinemia after long-term PPIs use is associated with development of fundic gland polyps (FGP) and hyperplasia of enterochromaffin-like cell (ECL) that might be concerned with gastric carcinoid tumor. Furthermore, several studies have posed the relationship between the risk of gastric cancer and long-term PPIs use with co-existing H. pylori infection. The present review summarize the recent accumulated evidence on neoplasm associated withsecondary hypergastrinemia after long-term PPIs use. (Korean J Med 2011;81:1-5)

참고문헌 (Reference)

1 김병욱, "장기간 위산분비억제제 투여가 혈청 가스트린, 크로모그라닌 A 및 그렐린의 발현에 미치는 영향" 대한소화기학회 53 (53): 84-89, 2009

2 김진수, "오메프라졸 투여 중지 후 저절로 사라진 다발 위저선 폴립 1예" 대한소화기학회 51 (51): 305-308, 2008

3 Rubin GP, "The use of long-term acid-suppression therapy" 49 : 119-120, 1995

4 Creutzfeldt W, "The achlorhydria-carcinoid sequence: role of gastrin" 39 : 61-79, 1988

5 Boutet R, "Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly" 13 : 813-817, 1999

6 Abraham SC, "Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene" 158 : 1005-1010, 2001

7 Kazantsev GB, "Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with lansoprazole and Nissen fundoplication: a case report" 55 : 600-602, 2002

8 Koop H, "Serum gastrin levels during long-term omeprazole treatment" 4 : 131-138, 1990

9 Fossmark R, "Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition" 43 : 20-24, 2008

10 Sanduleanu S, "Serum gastrin and chromogranin A during medium-and long-term acid suppressive therapy: a case-control study" 13 : 145-153, 1999

11 Thomson AB, "Safety of the long-term use of proton pump inhibitors" 16 : 2323-2330, 2010

12 Thomson AB, "Safety of the long-term use of proton pump inhibitors" 16 : 2323-2330, 2010

13 Raghunath AS, "Review article: the long-term use of proton-pump inhibitors" 22 (22): S55-S63, 2005

14 Goudie BM, "Repeat prescribing of ulcer healing drugs in general practice: prevalence and underlying diagnosis" 10 : 147-150, 1996

15 Freeman HJ, "Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis" 14 : 1318-1320, 2008

16 Håkanson R, "Proposed mechanism of induction of gastric carcinoids: the gastrin hypothesis" 20 (20): S65-S71, 1990

17 Tielemans Y, "Proliferation of enterochromaffinlike cells in omeprazole-treated hypergastrinemic rats" 96 : 723-729, 1989

18 Prach AT, "Prescription of acid-suppressing drugs in relation to endoscopic diagnosis: a record-linkage study" 13 : 397-405, 1999

19 Benet LZ, "Pharmacokinetics: a relevant factor for the choice of a drug" 8 (8): S25-S32, 1994

20 Cats A, "Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment" 31 : 684-690, 2000

21 Attard TM, "Multicenter experience with upper gastrointestinal polyps in pediatric patients with familial adenomatous polyposis" 99 : 681-686, 2004

22 Carmack SW, "Management of gastric polyps: a pathology-based guide for gastroenterologists" 6 : 331-341, 2009

23 Raghunath AS, "Long-term prescribing of proton pump inhibitors in primary care: a cross-sectional survey" 53 (53): A24-, 2004

24 Hungin AP, "Long-term prescribing of proton pump inhibitors in general practice" 49 : 451-453, 1999

25 Geboes K, "Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa" 15 : 1819-1826, 2001

26 Singh P, "Long term omeprazole therapy for reflux esophagitis:follow-up in serum gastrin levels, EC cell hyperplasia and neoplasia" 6 : 789-792, 2000

27 Ryder SD, "Levi AJ. Long term acid suppressing treatment in general practice" 308 : 827-830, 1994

28 Jalving M, "Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy" 24 : 1341-1348, 2006

29 Hurenkamp GJ, "How do primary care physicians use long-term acid suppressant drugs? A population-based analysis of Dutch general practices" 51 : 241-245, 2002

30 Jalving M, "High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature" 15 : 1229-1123, 2003

31 Uemura N, "Helicobacter pylori infection and the development of gastric cancer" 345 : 784-789, 2001

32 McColl KE, "Helicobacter pylori infection and long term proton pump inhibitor therapy" 53 : 5-7, 2004

33 Berstad AE, "Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole" 41 : 740-747, 1997

34 Eissele R, "Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia" 112 : 707-717, 1997

35 Hodgson N, "Gastric carcinoids: a temporal increase with proton pump introduction" 19 : 1610-1612, 2005

36 Abraham SC, "Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations" 157 : 747-754, 2000

37 el-Zimaity HM, "Fundic gland polyps developing during omeprazole therapy" 92 : 1858-1860, 1997

38 Zelter A, "Fundic gland polyps and association with proton pump inhibitor intake: a prospective study in 1,780 endoscopies" 56 : 1743-1748, 2011

39 Diebold MD, "Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls" 43 : 1629-1635, 1998

40 Lamberts R, "Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa" 64 : 205-213, 2001

41 Håkanson R, "ECL cells: biology and pathobiology" 55 (55): S38-S45, 1994

42 Bertoni G, "Dysplastic changes in gastric fundic gland polyps of patients with familial adenomatous polyposis" 31 : 192-197, 1999

43 Kuipers EJ, "Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomized controlled trial" 53 : 12-20, 2004

44 Majumdar SR, "Chronic acid-related disorders are common and underinvestigated" 98 : 2409-2414, 2003

45 Moayyedi P, "Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression" 5 : 206-214, 2000

46 Lundell L, "Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial" 23 : 639-647, 2006

47 Uemura N, "Changes in Helicobacter pyloriinduced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan" 14 : 1345-1352, 2000

48 Blankenhorn K, "Business watch: 2001 in review: despite economic challenges, pharmaceutical industry still maintains steady growth" 37 : 47-62, 2002

49 Kuipers EJ, "Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication" 334 : 1018-1022, 1996

50 Waldum HL, "Antiulcer drugs and gastric cancer" 50 (50): S39-S44, 2005

51 McCarthy DM, "Adverse effects of proton pump inhibitor drugs: clues and conclusions" 26 : 624-631, 2010

52 Modlin IM, "A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem" 99 : 23-32, 2004